ABBV AbbVie Inc. Common Stock
Sobre AbbVie Inc. Common Stock Visão geral da empresa da Wikipedia
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
Ler mais
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.
History
AbbVie was formed in 2012 as a corporate spin-off from Abbott Laboratories. It became a public company in January 2013.
In January 2014, the company acquired ImmuVen, a startup incubated at the University of Illinois Urbana-Champaign and focused on biotherapeutics to treat cancer, infectious disease, and autoimmune disorders.
In September 2014, AbbVie and Infinity Pharmaceuticals entered into a collaboration to develop and commercialize duvelisib, Infinity's PI3K inhibitor for the treatment of patients with cancer. On the same day, AbbVie and Calico entered into a research and development (R&D) collaboration intended to discover, develop and bring to market new therapies for patients with aging-associated diseases including neurodegeneration and cancer. California Life Company, operating as Calico, is an Alphabet Inc. subsidiary focused on aging and age-related diseases, and led by former Genentech chairman and CEO of Arthur D. Levinson and former Genentech EVP and chief medical officer Hal V. Barron (who subsequently left the company).
In October 2014, AbbVie ended its efforts to acquire Shire, which would have been one of the largest mergers and acquisitions (M&A) deals of that year and one of the largest tax inversions in history, due to changes in the US tax code by the US Treasury; AbbVie had to pay a $1.6 billion breakup fee.
In May 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers, ibrutinib; AstraZeneca had also been bidding to acquire Pharmacyclics. The Pharmacyclics name was retained, and it operated as a subsidiary of AbbVie from its previous Sunnyvale, California headquarters until the consolidation of AbbVie Bay Area sites in a new building in South San Francisco. In June 2015, AbbVie and Halozyme Therapeutics entered into a global collaboration and licensing agreement to develop and commercialize products that combine AbbVie's treatments and Halozyme's ENHANZE drug-delivery technology, this was terminated in November 2016.
In February 2016, AbbVie and Cambridge, Massachusetts-based Synlogic announced a multi-year R&D collaboration. Synlogic is a synthetic biology company built on research from the labs of James Collins and Tim Lu at MIT. As part of the collaboration, AbbVie is getting worldwide rights to Synlogic's probiotic-based technology for treating inflammatory bowel disease, and the research teams will focus on Crohn's disease and ulcerative colitis.
In April 2016, the company announced it would acquire Stemcentrx for up to $9.8 billion. A day later, the company announced an expansion of a two and a half-year-old cystic fibrosis deal with Galapagos NV, potentially doubling milestone payments to $600 million.
Also in April 2016, the company partnered with the University of Chicago to investigate several areas of oncology: breast, lung, prostate, colorectal and hematological cancers.
Also in April 2016, the company announced it would co-commercialize Argenx's preclinical immunotherapy, ARGX-115. ARGX-115 is a first-in-class immunotherapy targeting GARP (glycoprotein A repetitions predominant), a membrane protein believed to enhance the immunosuppressive effects of T cells. The company also announced a deal to co-develop/commercialize at least one of CytomX Probody's conjugates against CD71 (transferrin receptor 1).
In June 2019, AbbVie announced it would acquire Irish-based Allergan plc for about $63 billion; however the transaction was not structured as a tax inversion; AbbVie remained legally domiciled in the U.S. for tax purposes. To gain FTC approval, the company divested Allergan's late-stage gastrointestinal candidate brazikumab to AstraZeneca as well as two pancreatic replacement enzymes, Zenpep and Viokace, to Nestlé. In July 2019, the company announced it would acquire Mavupharma, boosting its cancer drug pipeline.
In March 2020, during the COVID-19 pandemic, AbbVie announced plans to evaluate the Kaletra/Aluvia HIV medicine as possible COVID-19 treatment. The company entered into various partnerships with health authorities in different countries to investigate the efficacy of the medication. However, the first non-blinded, randomized trial found the drug not useful to treat severe COVID-19. The Israeli government announced that it would force AbbVie to license its patents for Kaletra, the brand name of lopinavir/ritonavir, a fixed dose combination medication for the treatment and prevention of HIV/AIDS which was also thought to have some applicability to fighting COVID-19. In response, AbbVie announced that it would cease enforcing its patents on the drug entirely.
In May 2021, Allergan Aesthetics announced the acquisition of Soliton. In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma.
In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118. In October, the company acquired DJS Antibodies for $225 million, giving it access to an experimental drug for an aggressive lung disease as well as technology to develop certain antibody medicines. In January 2023, Humira began facing competition from biosimilars.
In February 2024, AbbVie acquired ImmunoGen for $10.1 billion, aiming to expedite its entry into the ovarian cancer treatment market with ImmunoGen's drug Elahere. In the same month, AbbVie and Tentarix Biotherapeutics announced the beginning of a long-term collaboration in the discovery and development of opportunistic, multi-specific biological candidates in oncology and immunology. AbbVie provides expertise in these areas, and will also provide Tentarix with option advances worth $64 million for two programs, and Tentarix will provide its patented Tentarix Tentacles™platform. AbbVie also received an option to purchase the software in full.
In March 2024, the company announced it would acquire Landos Biopharma for over $200 million. In June 2024, Robert Michael replaced Richard Gonzalez as CEO of AbbVie. Gonzalez became the executive chairman. In August 2024, AbbVie acquired neuroscience drugmaker Cerevel Therapeutics for $8.7 billion, in an attempt to expand its drug pipeline. In September 2024, AbbVie filed a lawsuit against BeiGene accusing it of stealing trade secrets to develop a competing therapy to treat blood and bone marrow cancers related to the growth of "B cells" after BeiGene hired a former longtime senior AbbVie scientist. In October 2024, AbbVie acquired Aliada Therapeutics for $1.4 billion to expand its neuroscience pipeline.
In January 2025, AbbVie acquired Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune area, for $200 million. In the same month, AbbVie announced a $1.64 billion partnership with Neomorph to develop new molecular glue degraders for multiple targets across oncology and immunology, as well as a $1 billion partnership with Simcere Zaiming to develop an investigational drug candidate for multiple myeloma. In May 2025, AbbVie entered into a collaboration and license option deal with ADARx Pharmaceuticals to develop a new type of RNA technology for disease areas like neuroscience, immunology, and oncology. In August 2025, AbbVie acquired Bretisilocin, which is under development for the treatment of major depressive disorder, from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
In January 2026, AbbVie struck a deal with the Trump administration to invest $100 billion in its US operations over the next 10 years and lower Medicaid prices. In exchange, the administration exempted AbbVie from tariffs and future pricing mandates.
Acquisition history
Major products
The company's major products are: Humira (adalimumab) ($9 billion in 2024 revenues, 16% of total revenues), approved to treat autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease and ulcerative colitis and administered via injection; Skyrizi (Risankizumab) ($11.7 billion in 2024 revenues, 21% of total revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases; Rinvoq (Upadacitinib) ($6.0 billion in 2023 revenues, 11% of total revenues), used to treat arthritis; and Botox ($6.0 billion in 2024 revenues, 11% of total revenues). Its other major products include Imbruvica (Ibrutinib) to treat cancer ($3.3 billion in 2024 revenues), Vraylar (Cariprazine) to treat schizophrenia and bipolar disorder ($3.3 billion in 2024 revenues), Venclexta (Venetoclax) to treat leukemia and lymphoma ($2.6 billion in 2024 revenues), Mavyret (Glecaprevir/pibrentasvir) to treat Hepatitis C ($1.3 billion in 2024 revenues), and Epkinly (epcoritamab), a blood-cancer therapy developed in partnership with Genmab ($0.1 billion in 2024 revenues). The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev (Foscarbidopa/foslevodopa) and tavapadon.
Legal issues
Anti-competitive practices
AbbVie has been accused of using anti-competitive patent thickets to prevent potentially cheaper biosimilars from entering the market. AbbVie and Alvotech, filed lawsuits against each other regarding a Humira biosimilar introduced by Alvotech. The lawsuits were settled out of court in 2022. Forest Laboratories, a subsidiary of AbbVie, was accused of using unlawful deals to prevent generic versions of its Alzheimer's disease drug, Namenda, from entering the market. In 2018, AbbVie agreed to pay $25 million to resolve allegations that it used kickback schemes to promote its cholesterol drug TriCor (fenofibrate). In 2020, AbbVie agreed to pay $24 million to resolve allegations that it used kickback schemes to promote Humira using "nurse ambassadors".
A report from the House Oversight and Reform Committee found that "AbbVie pursued a variety of tactics to increase drug sales while raising prices for Americans, including exploiting the patent system to extend its market monopoly, abusing orphan drug protections to further block competition, and engaging in anticompetitive pricing practices". Pursuant to the Inflation Reduction Act, the price of Imbruvica was reduced by 38%, to $9,319 per month, effective in 2026.
Tax avoidance
In June 2021, the United States Senate Finance Committee, under Chair Ron Wyden (D-OR), began an investigation to determine if the company took advantage of loopholes in the Tax Cuts and Jobs Act of 2017 to significantly reduce its tax liability. In a letter to AbbVie CEO Richard Gonzalez, Wyden noted the company suffered a 2020 pretax loss in the US of $4.5 billion and an overseas pretax profit of $7.9 billion the same year. The report, released in July 2022, showed that AbbVie was able to dodge U.S. taxes by registering intellectual property in offshore jurisdictions such as Bermuda. As a result, while AbbVie received 75% of its sales of Humira in the United States, it only reported 1% of that income for U.S. tax purposes.
Marketing of opioid painkillers
In July 2022 the company agreed to pay up to $2.37 billion to settle U.S. lawsuits against its Allergan unit over the marketing of opioid analgesics. AbbVie denied any wrongdoing.
Litigation by the company against the NHS
In 2018, AbbVie sued NHS England in the Technology and Construction Court claiming that the agency breached procurement rules and had not treated the company fairly when seeking suppliers for hepatitis C treatments. In 2019, a UK court dismissed AbbVie's case against the NHS.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
ABBV Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
ABBV Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos
| Data ex | Valor |
|---|---|
| 15 de Julho de 2026 | $1,7300 |
| 15 de Abril de 2026 | $1,7300 |
| 16 de Janeiro de 2026 | $1,7300 |
| 15 de Outubro de 2025 | $1,6400 |
| 15 de Julho de 2025 | $1,6400 |
| 15 de Abril de 2025 | $1,6400 |
| 15 de Janeiro de 2025 | $1,6400 |
| 15 de Outubro de 2024 | $1,5500 |
| 15 de Julho de 2024 | $1,5500 |
| 12 de Abril de 2024 | $1,5500 |
| 12 de Janeiro de 2024 | $1,5500 |
| 12 de Outubro de 2023 | $1,4800 |
| 13 de Julho de 2023 | $1,4800 |
| 13 de Abril de 2023 | $1,4800 |
| 12 de Janeiro de 2023 | $1,4800 |
| 13 de Outubro de 2022 | $1,4100 |
| 14 de Julho de 2022 | $1,4100 |
| 13 de Abril de 2022 | $1,4100 |
| 13 de Janeiro de 2022 | $1,4100 |
| 14 de Outubro de 2021 | $1,3000 |
ABBV Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
- Compra forte 9 23,7%
- Compra 22 57,9%
- Manter 7 18,4%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
29 analistas · 2026-08-18Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $3.65 | $3.68 | -0.03% |
| 31 de Março de 2026 | $2.65 | $2.65 | 0.00% |
| 31 de Dezembro de 2025 | $2.71 | $2.71 | 0.00% |
| 30 de Setembro de 2025 | $1.86 | $1.81 | 0.05% |
| 30 de Junho de 2025 | $2.97 | $2.94 | 0.03% |
| 31 de Março de 2025 | $2.46 | $2.43 | 0.03% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| ABBV | — | 96.8 | 8.6% | 6.9% | 15367.3% | — |
| AMGN | $176.35B | 23.0 | 10.0% | 21.0% | 95.9% | — |
| GILD | $152.32B | 18.1 | 2.4% | 28.9% | 40.5% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Cost of Revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B | $15.39B | $7.44B | $7.72B | $7.04B | $5.83B | $4.50B | $4.43B | |
| SG&A Expense | $14.01B | $14.75B | $12.87B | $15.26B | $12.35B | $11.30B | $6.94B | $7.40B | $6.29B | $5.88B | $6.39B | $7.72B | |
| Operating Expenses | $46.09B | $47.20B | $41.56B | $39.94B | $38.27B | $34.44B | $20.28B | $26.37B | $18.67B | $16.30B | $15.32B | $16.55B | |
| Operating Income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.54B | $9.34B | $7.54B | $3.41B | |
| Interest Expense | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B | $1.35B | $1.15B | $1.05B | $719M | $429M | |
| Other Non-op | $-5.79B | $-3.24B | $-4.68B | $-2.45B | $-2.50B | $-5.61B | $-3.01B | $-18M | $-466M | $-188M | $-13M | $27M | |
| Pretax Income | $6.60B | $3.72B | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B | $5.20B | $7.73B | $7.88B | $6.64B | $2.37B | |
| Income Tax | $2.36B | $-570M | $1.38B | $1.63B | $1.44B | $-1.22B | $544M | $-490M | $2.42B | $1.93B | $1.50B | $595M | |
| Net Income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| EPS (Basic) | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 | $3.67 | $3.31 | $3.65 | $3.15 | $1.11 | |
| EPS (Diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 | |
| Shares (Basic) | 1,769,000,000 | 1,769,000,000 | 1,768,000,000 | 1,771,000,000 | 1,770,000,000 | 1,667,000,000 | 1,481,000,000 | 1,541,000,000 | 1,596,000,000 | 1,622,000,000 | 1,625,000,000 | 1,595,000,000 | |
| Shares (Diluted) | 1,773,000,000 | 1,773,000,000 | 1,773,000,000 | 1,778,000,000 | 1,777,000,000 | 1,673,000,000 | 1,484,000,000 | 1,546,000,000 | 1,603,000,000 | 1,631,000,000 | 1,637,000,000 | 1,610,000,000 | |
| EBITDA | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.59B | $9.38B | $7.54B | $3.41B |
Balanço Patrimonial 26
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B | $8.45B | $39.92B | $7.29B | $9.30B | $5.10B | $8.40B | $8.35B | |
| Short-term Investments | $28M | $31M | $2M | $28M | $84M | $30M | $0 | $772M | $486M | $1.32B | $8M | $26M | |
| Receivables | $12.59B | $10.92B | $11.15B | $11.25B | $9.98B | $8.82B | $5.43B | $5.38B | $5.09B | $4.76B | $4.73B | · | |
| Inventory | $4.95B | $4.18B | $4.10B | $3.58B | $3.13B | $3.31B | $1.81B | $1.60B | $1.60B | $1.44B | $1.72B | $1.12B | |
| Prepaid Expense | $6.29B | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $29.06B | $25.58B | $33.00B | $28.46B | $27.93B | $24.17B | $49.52B | $16.95B | $21.22B | $16.19B | $16.31B | $16.08B | |
| PP&E (Net) | $5.63B | $5.13B | $4.99B | $4.93B | $5.11B | $5.25B | $2.96B | $2.88B | $2.80B | $2.60B | $2.56B | $2.48B | |
| PP&E (Gross) | $13.53B | $12.27B | $11.63B | $10.99B | $10.73B | $10.86B | $8.19B | $8.40B | $8.07B | $7.53B | $7.33B | $7.11B | |
| Accum. Depreciation | $7.90B | $7.13B | $6.65B | $6.05B | $5.62B | $5.61B | $5.23B | $5.51B | $5.27B | $4.92B | $4.77B | $4.62B | |
| Goodwill | $35.64B | $34.96B | $32.29B | $32.16B | $32.38B | $33.12B | $15.60B | $15.66B | $15.79B | $15.42B | $13.17B | $5.86B | |
| Intangibles | $52.64B | $60.07B | $55.61B | $67.44B | $75.95B | $82.88B | $18.65B | $21.23B | $27.56B | $28.90B | $19.71B | $1.51B | |
| Other Non-current Assets | $10.72B | $9.14B | $8.51B | $5.57B | $4.88B | $4.85B | $2.29B | $1.21B | $1.33B | $1.21B | $1.15B | $1.48B | |
| Total Assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B | |
| Accounts Payable | $34.73B | $2.94B | $3.69B | $2.93B | $2.88B | $2.28B | $1.45B | $1.55B | $1.47B | $1.41B | $1.60B | $1.40B | |
| Short-term Debt | $2.50B | $0 | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Current Liabilities | $43.29B | $38.75B | $37.84B | $29.54B | $35.19B | $28.66B | $15.59B | $17.24B | $16.64B | $9.78B | $10.89B | $11.39B | |
| Capital Leases | $689M | $697M | $735M | $754M | $713M | $832M | · | · | · | · | · | · | |
| Deferred Tax | $2.39B | $2.58B | $1.95B | $2.19B | $3.01B | $3.65B | $1.13B | $1.07B | $2.49B | $6.89B | $5.28B | $159M | |
| Other Non-current Liabilities | $32.57B | $30.13B | $32.33B | $30.66B | $28.70B | $27.61B | $17.60B | $1.31B | $1.24B | $1.16B | $844M | $990M | |
| Long-term Debt | $64.50B | $66.84B | $59.24B | $63.13B | $75.96B | $84.95B | $67.23B | · | · | · | · | · | |
| Total Debt | $2.50B | · | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Retained Earnings | $-15.49B | $-7.90B | $-1.00B | $4.78B | $3.13B | $1.05B | $4.72B | $3.37B | $5.46B | $4.38B | $2.25B | $535M | |
| Treasury Stock | $9.15B | $8.20B | $6.53B | $4.59B | $3.14B | $2.26B | $24.50B | $24.11B | $11.92B | $10.85B | $8.84B | $972M | |
| AOCI | $-1.14B | $-1.93B | $-2.31B | $-2.20B | $-2.90B | $-3.12B | $-3.60B | $-2.48B | $-2.73B | $-2.59B | $-2.56B | $-2.03B | |
| Stockholders' Equity | $-3.27B | $3.33B | $10.36B | $17.25B | $15.41B | $13.08B | $-8.17B | $-8.45B | $5.10B | $4.64B | $3.94B | $1.74B | |
| Liabilities + Equity | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B |
Fluxo de Caixa 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $955M | $911M | $747M | $671M | $692M | $753M | $430M | $421M | $365M | $353M | $282M | $241M | |
| Deferred Tax | $-492M | $-1.45B | $-2.89B | $-1.93B | $-898M | $-2.33B | $122M | $-1.52B | $-4.16B | $-796M | $152M | $-380M | |
| Amort. of Intangibles | $7.38B | $7.62B | $7.95B | $7.69B | $7.72B | $5.80B | $1.55B | $1.29B | $1.08B | $764M | $419M | $403M | |
| Restructuring | · | · | · | · | · | · | $219M | $59M | $86M | $52M | $126M | $16M | |
| Operating Cash Flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B | $13.43B | $9.96B | $7.04B | $7.54B | $3.55B | |
| CapEx | $1.21B | $974M | $777M | $695M | $787M | $798M | $552M | $638M | $529M | $479M | $532M | $612M | |
| Investing Cash Flow | $-6.64B | $-20.82B | $-2.01B | $-623M | $-2.34B | $-37.56B | $596M | $-1.01B | $-274M | · | · | · | |
| Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Net Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Stock Repurchased | $980M | $1.71B | $1.97B | $1.49B | $934M | $978M | $629M | $12.01B | $1.41B | $6.03B | $7.59B | $665M | |
| Net Stock Activity | $-980M | $-1.71B | $-1.97B | $-1.49B | $-934M | $-978M | $-629M | $-12.01B | $-1.41B | $-6.03B | $-7.57B | $-652M | |
| Dividends Paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B | |
| Financing Cash Flow | $-12.72B | $-5.21B | $-17.22B | $-24.80B | $-19.04B | $-11.50B | $18.71B | $-14.40B | $-5.51B | $-3.93B | · | · | |
| Net Change in Cash | $-295M | $-7.29B | $3.61B | $-545M | $1.30B | $-31.48B | $32.63B | $-2.01B | $4.20B | $-3.30B | $51M | $-1.25B | |
| Taxes Paid | $3.63B | $4.10B | $4.70B | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B | $16.79B | $12.77B | $12.79B | $9.43B | $6.56B | $7.00B | $2.94B | |
| Levered FCF | $15.96B | $14.59B | $20.33B | $22.29B | $19.84B | $13.45B | $11.10B | $11.31B | $8.64B | $5.77B | $6.45B | $2.62B |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| Net Margin | 6.9% | 7.6% | 8.9% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% | · | · | |
| Pretax Margin | 10.8% | 6.6% | 11.5% | 23.2% | 23.1% | 7.4% | 25.3% | 15.9% | 27.4% | 30.8% | 29.1% | 11.9% | |
| EBITDA Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| ROA | 3.1% | 3.2% | 3.6% | 8.3% | 7.8% | 3.9% | 10.6% | 8.7% | 7.8% | 10.0% | · | · | |
| ROE | 15367.3% | 62.5% | 35.2% | 72.5% | 81.0% | 188.2% | -94.2% | -100.1% | 109.1% | 138.8% | · | · | |
| ROIC | -1254.6% | 317.0% | 96.0% | 92.3% | 103.3% | 117.9% | -148.6% | -147.1% | 119.9% | 141.3% | 134.1% | 117.9% |
Liquidez e Solvência 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 | 0.8 | 3.2 | 1.0 | 1.3 | 1.7 | 1.5 | 1.4 | |
| Quick Ratio | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 | 0.6 | 2.9 | 0.8 | 0.6 | 0.7 | 0.8 | 0.7 | |
| Debt / Equity | -0.8 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.4 | 0.1 | 0.1 | 0.1 | 0.2 | |
| Interest Coverage | 5.2 | 3.3 | 5.7 | 8.1 | 7.4 | 4.6 | 7.3 | 4.7 | 8.3 | 9.0 | 10.5 | 8.0 |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.6 | 0.7 | |
| Inventory Turnover | 4.0 | 4.1 | 5.3 | 5.2 | 5.4 | 6.0 | 4.4 | 4.8 | 4.6 | 3.7 | 3.2 | 3.9 | |
| Receivables Turnover | 5.2 | 5.1 | 4.8 | 5.5 | 6.0 | 6.4 | 6.2 | 6.3 | · | · | · | · |
Taxas de Crescimento 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.6% | 3.7% | -6.4% | 3.3% | 22.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.8% | 0.08% | 5.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -1.3% | -12.1% | -59.0% | 2.8% | 137.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -29.1% | -28.2% | 0.00% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -2.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -1.2% | -12.0% | -58.9% | 2.5% | 150.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -29.1% | -28.2% | 1.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -1.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 8.6% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 6
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Net Income TTM | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| P/E | 96.8 | 74.4 | 57.0 | 24.4 | 21.0 | 39.4 | 16.8 | 25.2 | 29.3 | 17.3 | 18.9 | 59.5 | |
| Earnings Yield | 1.0% | 1.3% | 1.8% | 4.1% | 4.8% | 2.5% | 6.0% | 4.0% | 3.4% | 5.8% | 5.3% | 1.7% | |
| Payout Ratio | 275.8% | 257.7% | 216.7% | 84.9% | 80.2% | 167.2% | 80.8% | 98.1% | 77.4% | 62.4% | · | · | |
| Annual Payout | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B |
Demonstração de Resultados 17
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B | $14.46B | $14.46B | $12.31B | $14.30B | $13.93B | $13.87B | $12.22B | $15.12B | $14.81B | |
| Cost of Revenue | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | $4.00B | $4.40B | $4.21B | $4.20B | $4.09B | $5.70B | $6.49B | $4.24B | $3.99B | $4.17B | $5.02B | |
| Gross Profit | · | · | $12.07B | · | · | · | $10.71B | · | · | · | $8.60B | · | · | · | $10.95B | · | |
| SG&A Expense | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | $3.29B | $3.85B | $4.21B | $3.38B | $3.31B | $3.19B | $3.37B | $3.27B | $3.04B | $3.42B | $3.30B | |
| Operating Expenses | $10.56B | $11.01B | $12.07B | $13.87B | $10.53B | $9.61B | $16.59B | $10.63B | $10.46B | $9.51B | $11.11B | $11.65B | $9.35B | $9.46B | $9.62B | $10.21B | |
| Operating Income | $6.43B | $3.99B | $4.54B | $1.90B | $4.89B | $3.73B | $-1.49B | $3.83B | $4.00B | $2.80B | $3.19B | $2.28B | $4.51B | $2.77B | $5.50B | $4.60B | |
| Interest Expense | $746M | $717M | $714M | $739M | $740M | $700M | $702M | $720M | $726M | $660M | $564M | $555M | $552M | $553M | $566M | $560M | |
| Interest Income | $67M | $72M | · | $72M | $62M | $73M | · | $129M | $220M | $207M | · | $157M | $98M | $99M | · | $63M | |
| Other Non-op | $-1.48B | $-2.31B | $-1.21B | $-503M | $-2.66B | $-1.45B | $-150M | $-1.16B | $-1.34B | $-586M | $-1.56B | $95M | $-1.41B | $-1.80B | $-2.02B | $330M | |
| Pretax Income | $4.28B | $1.04B | $2.67B | $714M | $1.55B | $1.66B | $-2.27B | $2.08B | $2.15B | $1.75B | $1.21B | $1.95B | $2.61B | $475M | $2.96B | $4.40B | |
| Income Tax | $662M | $342M | $853M | $526M | $613M | $372M | $-2.25B | $520M | $773M | $383M | $388M | $172M | $583M | $234M | $493M | $448M | |
| Net Income | $3.61B | $695M | $1.82B | $186M | $938M | $1.29B | $-22M | $1.56B | $1.37B | $1.37B | $822M | $1.78B | $2.02B | $239M | $2.47B | $3.95B | |
| EPS (Basic) | $2.04 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.02 | $0.88 | $0.77 | $0.77 | $0.46 | $1.00 | $1.14 | $0.13 | $1.39 | $2.22 | |
| EPS (Diluted) | $2.03 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.03 | $0.88 | $0.77 | $0.77 | $0.45 | $1.00 | $1.14 | $0.13 | $1.40 | $2.21 | |
| Shares (Basic) | 1,769,000,000 | 1,770,000,000 | -3,536,000,000 | 1,769,000,000 | 1,768,000,000 | 1,768,000,000 | -3,537,000,000 | 1,769,000,000 | 1,768,000,000 | 1,769,000,000 | -3,536,000,000 | 1,767,000,000 | 1,767,000,000 | 1,770,000,000 | -3,541,000,000 | 1,771,000,000 | |
| Shares (Diluted) | 1,771,000,000 | 1,774,000,000 | -3,542,000,000 | 1,772,000,000 | 1,771,000,000 | 1,772,000,000 | -3,543,000,000 | 1,772,000,000 | 1,771,000,000 | 1,773,000,000 | -3,545,000,000 | 1,771,000,000 | 1,771,000,000 | 1,776,000,000 | -3,552,000,000 | 1,776,000,000 | |
| EBITDA | $6.43B | $3.99B | · | $1.90B | $4.89B | $3.73B | · | $3.83B | $4.00B | $2.80B | · | $2.28B | $4.51B | $2.77B | · | $4.60B |
Balanço Patrimonial 26
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B | $5.52B | $7.26B | $13.13B | $18.07B | · | $13.29B | $8.76B | $6.71B | · | $11.83B | |
| Short-term Investments | · | · | $28M | $42M | $0 | $1M | $31M | $28M | $27M | $2M | · | $3M | $7M | $11M | · | $47M | |
| Receivables | $13.82B | $12.48B | $12.59B | $12.77B | $12.64B | $12.48B | $10.92B | $11.47B | $11.72B | $11.95B | · | $11.41B | $11.49B | $11.47B | · | $10.74B | |
| Inventory | $5.13B | $5.05B | $4.95B | $4.94B | $4.96B | $4.53B | $4.18B | $4.45B | $4.22B | $4.25B | · | $3.98B | $4.05B | $3.83B | · | $3.17B | |
| Prepaid Expense | $8.15B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $33.67B | $33.53B | $29.06B | $28.54B | $29.26B | $27.68B | $25.58B | $27.79B | $33.82B | $38.87B | · | $33.22B | $28.85B | $26.49B | · | $30.36B | |
| PP&E (Net) | $5.80B | $5.69B | $5.63B | $5.48B | $5.28B | $5.24B | $5.13B | $5.14B | $5.02B | $4.98B | · | $4.93B | $4.94B | $4.93B | · | $4.89B | |
| PP&E (Gross) | $13.96B | $13.73B | $13.53B | $13.23B | $12.93B | $12.57B | $12.27B | $12.28B | $11.90B | $11.72B | · | $11.37B | $11.32B | $11.14B | · | $10.68B | |
| Accum. Depreciation | $8.16B | $8.04B | $7.90B | $7.75B | $7.65B | $7.33B | $7.13B | $7.14B | $6.88B | $6.75B | · | $6.44B | $6.38B | $6.21B | · | $5.79B | |
| Goodwill | $35.52B | $35.57B | $35.64B | $35.63B | $35.64B | $35.28B | $34.96B | $35.30B | $33.39B | $33.43B | $32.29B | $32.09B | $32.22B | $32.22B | $32.16B | $31.73B | |
| Intangibles | $49.14B | $50.87B | $52.64B | $54.31B | $57.03B | $58.49B | $60.07B | $66.65B | $60.24B | $62.23B | · | $58.60B | $62.86B | $64.85B | · | $68.72B | |
| Other Non-current Assets | $10.73B | $10.54B | $10.72B | $9.64B | $9.66B | $9.19B | $9.14B | $8.29B | $9.20B | $9.07B | · | $7.09B | $6.20B | $5.80B | · | $5.38B | |
| Total Assets | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B | |
| Accounts Payable | $33.30B | $33.77B | $3.59B | $33.62B | $32.24B | $31.04B | $2.94B | $30.49B | $29.33B | $31.33B | · | $29.66B | $27.04B | $24.79B | · | $23.50B | |
| Short-term Debt | $0 | $0 | $2.50B | $3.79B | $5.56B | $1.59B | $0 | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Current Liabilities | $41.64B | $42.10B | $43.29B | $39.39B | $39.77B | $36.40B | $38.75B | $43.06B | $41.91B | $41.52B | · | $34.77B | $32.24B | $27.59B | · | $32.71B | |
| Capital Leases | · | · | $689M | · | · | · | $697M | · | · | · | · | · | · | · | · | · | |
| Deferred Tax | $2.28B | $2.33B | $2.39B | $2.48B | $2.55B | $2.58B | $2.58B | $2.75B | $2.73B | $2.72B | · | $2.04B | $2.12B | $2.11B | · | $1.97B | |
| Other Non-current Liabilities | $34.60B | $34.11B | $32.57B | $31.66B | $32.04B | $31.19B | $30.13B | $33.03B | $32.43B | $32.78B | · | $31.64B | $32.29B | $32.25B | · | $30.21B | |
| Long-term Debt | · | · | $64.50B | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $0 | $0 | · | $3.79B | $5.56B | $1.59B | · | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Retained Earnings | $-17.33B | $-17.87B | $-15.49B | $-14.23B | $-11.50B | $-9.53B | $-7.90B | $-4.96B | $-3.77B | $-2.38B | · | $933M | $1.79B | $2.39B | · | $4.95B | |
| Treasury Stock | $10.62B | $10.61B | $9.15B | $9.14B | $9.15B | $9.14B | $8.20B | $7.85B | $7.84B | $7.83B | · | $6.53B | $6.53B | $6.52B | · | $4.59B | |
| AOCI | $-1.16B | $-1.15B | $-1.14B | $-1.57B | $-1.54B | $-1.74B | $-1.93B | $-2.33B | $-2.51B | $-2.45B | · | $-2.35B | $-2.25B | $-2.23B | · | $-3.44B | |
| Stockholders' Equity | $-5.93B | $-6.66B | $-3.27B | $-2.64B | $-183M | $1.42B | $3.33B | $6.03B | $6.78B | $8.01B | · | $12.09B | $12.87B | $13.27B | · | $15.99B | |
| Liabilities + Equity | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B |
Fluxo de Caixa 15
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $166M | $444M | $157M | $209M | $179M | $410M | $164M | $181M | $218M | $348M | $125M | $130M | $179M | $313M | $132M | $126M | |
| Deferred Tax | $-195M | $137M | $-385M | $193M | $-272M | $-28M | $-767M | $-277M | $-16M | $-389M | $-1.39B | $-863M | $-368M | $-267M | $-516M | $-621M | |
| Amort. of Intangibles | $1.70B | $1.75B | $1.72B | $1.90B | $1.90B | $1.86B | $1.93B | $1.90B | $1.90B | $1.89B | $1.90B | $2.00B | $2.10B | $1.95B | $2.03B | $2.00B | |
| Operating Cash Flow | $3.44B | $3.83B | $5.22B | $7.02B | $5.15B | $1.64B | $7.05B | $5.45B | $2.27B | $4.04B | $4.75B | $7.57B | $6.32B | $4.19B | $7.43B | $7.60B | |
| CapEx | $322M | $265M | $329M | $381M | $269M | $235M | $291M | $249M | $241M | $193M | $205M | $219M | $178M | $175M | $213M | $177M | |
| Investing Cash Flow | $-1.20B | $-574M | $-1.46B | $-3.26B | $-1.18B | $-735M | $-1.87B | $-8.26B | $-1.10B | $-9.59B | $-800M | $-369M | $-341M | $-499M | $-448M | $1.29B | |
| Debt Issued | $0 | $7.99B | $0 | $0 | $0 | $3.99B | $2.00B | $0 | $0 | $14.96B | · | $0 | $0 | $0 | $0 | $0 | |
| Net Debt Issued | · | $7.99B | · | · | · | $3.99B | · | · | · | $14.96B | · | · | · | $0 | · | · | |
| Stock Repurchased | $9M | $1.49B | $3M | $4M | $12M | $961M | $358M | $17M | $9M | $1.32B | $3M | $4M | $10M | $1.96B | $4M | $4M | |
| Net Stock Activity | · | $-1.49B | · | · | · | $-961M | · | · | · | $-1.32B | · | · | · | $-1.96B | · | · | |
| Dividends Paid | $3.07B | $3.09B | $2.91B | $2.91B | $2.91B | $2.92B | $2.75B | $2.75B | $2.75B | $2.77B | $2.63B | $2.63B | $2.62B | $2.66B | $2.51B | $2.50B | |
| Financing Cash Flow | $-5.05B | $919M | $-4.17B | $-4.59B | $-2.71B | $-1.26B | $-6.86B | $-3.07B | $-6.10B | $10.82B | $-4.45B | $-2.66B | $-3.92B | $-6.19B | $-9.63B | $-5.52B | |
| Net Change in Cash | $-2.82B | $4.16B | $-400M | $-838M | $1.29B | $-349M | $-1.73B | $-5.87B | $-4.94B | $5.25B | $-473M | $4.53B | $2.05B | $-2.49B | $-2.63B | $3.31B | |
| Free Cash Flow | · | $3.56B | · | · | · | $1.40B | · | · | · | $3.85B | · | · | · | $4.02B | · | · | |
| Levered FCF | · | $3.08B | · | · | · | $857M | · | · | · | $3.33B | · | · | · | $3.74B | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| Net Margin | 21.3% | 4.6% | · | 1.2% | 6.1% | 9.6% | · | 10.8% | 9.5% | 11.1% | · | 12.8% | 14.6% | 2.0% | · | 26.7% | |
| Pretax Margin | 25.2% | 6.9% | · | 4.5% | 10.1% | 12.4% | · | 14.4% | 14.8% | 14.3% | · | 14.0% | 18.8% | 3.9% | · | 29.7% | |
| EBITDA Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| ROA | 2.6% | 0.51% | · | 0.13% | 0.67% | 0.90% | · | 1.1% | 0.99% | 0.97% | · | 1.3% | 1.5% | 0.17% | · | 2.7% | |
| ROE | -118.1% | -26.6% | · | 11.0% | 28.4% | 27.3% | · | 17.2% | 14.0% | 12.9% | · | 12.7% | 14.7% | 1.6% | · | 26.7% | |
| ROIC | -91.6% | -40.2% | · | 43.7% | 55.2% | 96.2% | · | 47.7% | 37.7% | 27.3% | · | 17.2% | 27.2% | 10.6% | · | 25.8% |
Liquidez e Solvência 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 0.8 | · | 0.7 | 0.7 | 0.8 | · | 0.6 | 0.8 | 0.9 | · | 1.0 | 0.9 | 1.0 | · | 0.9 | |
| Quick Ratio | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.4 | 0.6 | 0.7 | · | 0.7 | 0.6 | 0.7 | · | 0.7 | |
| Debt / Equity | 0.0 | 0.0 | · | -1.4 | -30.4 | 1.1 | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Interest Coverage | 8.6 | 5.6 | · | 2.6 | 6.6 | 5.3 | · | 5.3 | 5.5 | 4.2 | · | 4.1 | 8.2 | 5.0 | · | 8.2 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.9 | 0.9 | · | 1.1 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.8 | 1.1 | 1.1 | · | 1.6 | |
| Receivables Turnover | 1.3 | 1.2 | · | 1.3 | 1.3 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.5 |
Avaliação (TTM) 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $64.39B | $62.82B | · | $59.64B | $58.33B | $57.37B | · | $55.53B | $55.00B | $54.40B | · | $55.14B | $56.02B | $56.74B | · | $57.82B | |
| Net Income TTM | $6.31B | $3.63B | · | $2.39B | $3.76B | $4.20B | · | $5.12B | $5.34B | $5.99B | · | $6.51B | $8.69B | $7.58B | · | $13.41B | |
| P/E | 71.1 | 107.1 | · | 175.4 | 88.4 | 89.2 | · | 68.6 | 57.2 | 54.0 | · | 40.8 | 27.7 | 37.7 | · | 17.9 | |
| Earnings Yield | 1.4% | 0.93% | · | 0.57% | 1.1% | 1.1% | · | 1.5% | 1.8% | 1.8% | · | 2.5% | 3.6% | 2.6% | · | 5.6% | |
| Payout Ratio | · | 444.0% | · | · | · | 227.5% | · | · | · | 202.5% | · | · | · | 1113.4% | · | · |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Margem Operacional % | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% |
| Lucro líquido | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| EPS Diluído | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | -0.8 | — | 0.0 | 0.0 | 0.0 |
| Índice de liquidez corrente | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 |
| Índice de Liquidez Seca | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B |
Últimas notícias Notícias recentes mencionando esta empresa
- Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
- How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?
- AbbVie Já é uma "Dividend King". Veja Por Que o Negócio de US$ 10,9 Bilhões com a Apogee Pode Criar Uma Dinastia
- AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
- AbbVie (ABBV) to Acquire Apogee Therapeutics
- Is AbbVie a Buy After Its Purchase of Apogee?
- Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
- AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
- Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger
- The $11 Billion Reason Abbvie Stock Is Up Today
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 4.559 declarantes · $203.7B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 248 (+10 vs trimestre anterior) | 102 (-73 vs trimestre anterior) | 1.873 (+177 vs trimestre anterior) | 1.507 (-178 vs trimestre anterior) | +62.9M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $29.038.274.101 | 115.396.098 | 14,25% | Ações |
| STATE STREET CORP | $20.784.645.667 | 82.596.748 | 10,20% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12.199.002.913 | 48.477.996 | 5,99% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $10.348.337.446 | 41.208.853 | 5,08% | Ações |
| Capital Research Global Investors | $7.574.798.407 | 30.101.551 | 3,72% | Ações |
| NORGES BANK | $6.430.543.942 | 25.554.538 | 3,16% | Ações |
| Capital World Investors | $4.826.436.854 | 19.178.966 | 2,37% | Ações |
| Capital International Investors | $3.936.357.038 | 15.638.631 | 1,93% | Ações |
| FMR LLC | $3.669.614.638 | 14.582.795 | 1,80% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3.235.535.863 | 12.854.734 | 1,59% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $2.501.249.007 | 9.939.791 | 1,23% | Ações |
| Fisher Asset Management, LLC | $2.390.069.445 | 9.497.970 | 1,17% | Ações |
| VANGUARD GROUP INC | $2.321.825.812 | 10.161.608 | 1,14% | Ações |
| AMERIPRISE FINANCIAL INC | $2.300.268.904 | 9.140.996 | 1,13% | Ações |
| UBS Group AG | $1.821.262.870 | 7.237.573 | 0,89% | Ações |
| RAYMOND JAMES FINANCIAL INC | $1.804.931.470 | 7.172.673 | 0,89% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $1.626.458.497 | 6.463.432 | 0,80% | Ações |
| BANK OF AMERICA CORP /DE/ | $1.288.677.353 | 5.121.115 | 0,63% | Ações |
| BlackRock, Inc. | $1.281.498.844 | 5.092.588 | 0,63% | Ações |
| Swiss National Bank | $1.255.358.984 | 4.988.710 | 0,62% | Ações |
| GOLDMAN SACHS GROUP INC | $1.238.268.174 | 4.920.792 | 0,61% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $1.229.678.938 | 4.886.670 | 0,60% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $1.194.403.724 | 4.746.478 | 0,59% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $1.092.298.708 | 4.340.720 | 0,54% | Ações |
| LPL Financial LLC | $1.030.798.580 | 4.096.323 | 0,51% | Ações |
| National Pension Service | $1.008.968.950 | 4.009.573 | 0,50% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.005.413.025 | 3.995.442 | 0,49% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $992.857.195 | 3.945.546 | 0,49% | Ações |
| Vanguard Global Advisers, LLC | $963.609.833 | 3.829.319 | 0,47% | Ações |
| Robeco Institutional Asset Management B.V. | $897.126.545 | 3.565.119 | 0,44% | Ações |
| Legal & General Group Plc | $895.484.594 | 3.558.594 | 0,44% | Ações |
| ALLIANCEBERNSTEIN L.P. | $890.041.939 | 4.092.335 | 0,44% | Ações |
| California Public Employees Retirement System | $862.671.241 | 3.428.196 | 0,42% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $817.473.174 | 3.248.582 | 0,40% | Ações |
| CITADEL ADVISORS LLC | $797.644.194 | 3.169.783 | 0,39% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $768.828.394 | 3.055.271 | 0,38% | Ações |
| BARCLAYS PLC | $739.133.865 | 2.937.267 | 0,36% | Ações |
| NORDEA INVESTMENT MANAGEMENT AB | $721.397.794 | 2.869.636 | 0,35% | Ações |
| RHUMBLINE ADVISERS | $687.895.224 | 2.733.648 | 0,34% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $667.358.842 | 2.652.038 | 0,33% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $655.267.540 | 2.603.988 | 0,32% | Ações |
| TD Asset Management Inc | $648.811.716 | 2.578.333 | 0,32% | Ações |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $631.733.198 | 2.904.654 | 0,31% | Ações |
| PNC Financial Services Group, Inc. | $625.922.542 | 2.487.373 | 0,31% | Ações |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $584.076.068 | 2.321.078 | 0,29% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $582.914.088 | 2.680.188 | 0,29% | Ações |
| FIFTH THIRD BANCORP | $541.376.862 | 2.151.394 | 0,27% | Ações |
| Assenagon Asset Management S.A. | $527.911.026 | 2.097.882 | 0,26% | Ações |
| JANE STREET GROUP, LLC | $520.089.552 | 2.066.800 | 0,26% | Opção de compra |
| CITADEL ADVISORS LLC | $500.839.092 | 1.990.300 | 0,25% | Opção de compra |
| JANE STREET GROUP, LLC | $499.555.728 | 1.985.200 | 0,25% | Opção de venda |
| HighTower Advisors, LLC | $495.062.218 | 1.967.343 | 0,24% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $485.540.135 | 1.929.503 | 0,24% | Ações |
| GQG Partners LLC | $483.559.978 | 1.921.614 | 0,24% | Ações |
| PRUDENTIAL FINANCIAL INC | $478.733.776 | 1.902.455 | 0,23% | Ações |
| Fayez Sarofim & Co | $464.570.323 | 1.846.170 | 0,23% | Ações |
| CAPTRUST FINANCIAL ADVISORS | $457.328.195 | 1.817.391 | 0,22% | Ações |
| US BANCORP \DE\ | $431.161.990 | 1.713.408 | 0,21% | Ações |
| MACKENZIE FINANCIAL CORP | $429.747.269 | 1.707.786 | 0,21% | Ações |
| AVIVA PLC | $418.894.036 | 1.664.656 | 0,21% | Ações |
| AMERICAN CENTURY COMPANIES INC | $417.685.426 | 1.659.851 | 0,21% | Ações |
| Caisse de depot et placement du Quebec | $413.100.025 | 1.641.631 | 0,20% | Ações |
| Baird Financial Group, Inc. | $408.320.931 | 1.622.639 | 0,20% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $402.263.652 | 1.598.568 | 0,20% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $398.029.187 | 1.581.740 | 0,20% | Ações |
| Eurizon Capital SGR S.p.A. | $382.266.246 | 1.515.159 | 0,19% | Ações |
| MILLENNIUM MANAGEMENT LLC | $381.605.769 | 1.516.475 | 0,19% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $379.803.020 | 1.509.311 | 0,19% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $358.269.921 | 1.448.017 | 0,18% | Ações |
| APG Asset Management N.V. | $355.105.573 | 1.613.385 | 0,17% | Ações |
| CINCINNATI INSURANCE CO | $353.604.528 | 1.405.200 | 0,17% | Ações |
| CITADEL ADVISORS LLC | $352.698.624 | 1.401.600 | 0,17% | Opção de venda |
| Alecta Tjanstepension Omsesidigt | $350.097.440 | 1.393.700 | 0,17% | Ações |
| UBS Group AG | $347.253.386 | 1.379.961 | 0,17% | Opção de compra |
| ROYAL LONDON ASSET MANAGEMENT LTD | $337.822.422 | 1.342.483 | 0,17% | Ações |
| Korea Investment CORP | $324.892.907 | 1.291.102 | 0,16% | Ações |
| BLAIR WILLIAM & CO/IL | $324.076.456 | 1.287.857 | 0,16% | Ações |
| CIBC Bancorp USA Inc. | $319.137.398 | 1.268.149 | 0,16% | Ações |
| NEUBERGER BERMAN GROUP LLC | $312.155.419 | 1.240.484 | 0,15% | Ações |
| KEYBANK NATIONAL ASSOCIATION/OH | $297.253.749 | 1.181.266 | 0,15% | Ações |
| PFA Pension, Forsikringsaktieselskab | $296.007.110 | 1.176.312 | 0,15% | Ações |
| Candriam S.C.A. | $292.814.436 | 1.164.745 | 0,14% | Ações |
| BANK OF MONTREAL /CAN/ | $287.298.646 | 1.141.705 | 0,14% | Ações |
| MENORA MIVTACHIM HOLDINGS LTD. | $286.660.236 | 1.139.168 | 0,14% | Ações |
| Quantinno Capital Management LP | $286.551.564 | 1.138.736 | 0,14% | Ações |
| CITIGROUP INC | $284.177.052 | 1.129.300 | 0,14% | Opção de venda |
| D. E. Shaw & Co., Inc. | $279.166.396 | 1.109.388 | 0,14% | Ações |
| Nuveen, LLC | $278.124.451 | 1.105.247 | 0,14% | Ações |
| Public Sector Pension Investment Board | $273.989.658 | 1.088.816 | 0,13% | Ações |
| STOREBRAND ASSET MANAGEMENT AS | $271.386.191 | 1.078.470 | 0,13% | Ações |
| ProShare Advisors LLC | $270.105.595 | 1.073.381 | 0,13% | Ações |
| Aberdeen Group plc | $269.639.809 | 1.071.530 | 0,13% | Ações |
| Guinness Asset Management LTD | $261.219.378 | 1.042.337 | 0,13% | Ações |
| TRUIST FINANCIAL CORP | $259.417.636 | 1.030.908 | 0,13% | Ações |
| Cerity Partners LLC | $251.309.055 | 998.667 | 0,12% | Ações |
| Cetera Investment Advisers | $249.297.571 | 990.692 | 0,12% | Ações |
| JONES FINANCIAL COMPANIES LLLP | $246.700.034 | 973.752 | 0,12% | Ações |
| COMMONWEALTH EQUITY SERVICES, LLC | $245.375.470 | 975.105 | 0,12% | Ações |
| FEDERATED HERMES, INC. | $244.359.552 | 971.068 | 0,12% | Ações |
| SATURNA CAPITAL CORP | $240.562.538 | 958.069 | 0,12% | Ações |
Executivos da empresa 38 insiders · 20 diretores · 15 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Robert A. Michael | CHIEF EXECUTIVE OFFICER | 28 de Fevereiro de 2025 F | 132.821 | 0 | 0 | $0 |
| Scott T Reents | EVP, CHIEF FINANCIAL OFFICER | 14 de Março de 2025 S | 11.577 | 0 | 0 | $0 |
| Nicholas Donoghoe | EVP, CHIEF BUS/STRAT OFFICER | 14 de Agosto de 2026 M | 74.430 | 0 | 1 | $-8.177.500 |
| Azita Saleki-Gerhardt | EVP, CHIEF OPERATIONS OFFICER | 12 de Agosto de 2025 M | 177.292 | 0 | 0 | $0 |
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | 31 de Março de 2025 M | 53.234 | 0 | 0 | $0 |
| Perry C Siatis | EVP, GC AND SECRETARY | 3 de Março de 2025 D | 4.619 | 0 | 0 | $0 |
| Timothy J. Richmond | EVP, CHIEF HR OFFICER | 3 de Março de 2025 S | 6.130 | 0 | 0 | $0 |
| Roopal Thakkar | EVP, R&D and CSO | 28 de Fevereiro de 2025 F | 42.276 | 0 | 0 | $0 |
| Kevin K Buckbee | SVP, CONTROLLER | 28 de Fevereiro de 2025 F | 7.797 | 0 | 0 | $0 |
| Thomas J Hudson | SVP, CSO, GLOBAL RESEARCH | 28 de Fevereiro de 2024 F | 107.267 | 0 | 0 | $0 |
| Carrie C Strom | SVP & PRES GLOBAL ALLERG AESTH | 11 de Maio de 2023 F | 28.024 | 0 | 0 | $0 |
| Elaine K. Sorg | SVP, US COMMERCIAL OPERATIONS | 25 de Abril de 2023 M | 35.330 | 0 | 0 | $0 |
| Brian L Durkin | VP, CONTROLLER | 28 de Fevereiro de 2023 F | 33.149 | 0 | 0 | $0 |
| Michael Severino | Vice Chairman | 23 de Maio de 2022 M | 152.103 | 0 | 0 | $0 |
| Henry O Gosebruch | EVP, Chief Strategy Officer | 16 de Maio de 2022 M | 41.623 | 0 | 0 | $0 |
| Laura J Schumacher | Vice Chairman | 25 de Fevereiro de 2022 F | 248.002 | 0 | 0 | $0 |
| Carlos Alban | Vice Chairman | 16 de Novembro de 2020 M | 114.899 | 0 | 0 | $0 |
| William J Chase | EVP, Finance & Administration | 26 de Junho de 2019 P | 169.552 | 0 | 0 | $0 |
| Thomas A. Hurwich | VP, Controller | 28 de Fevereiro de 2017 F | 62.329 | 0 | 0 | $0 |
| John M. Leonard | SVP, Chief Scientific Officer | 15 de Março de 2013 M | 107.320 | 0 | 0 | $0 |
| Susan E Quaggin | Conselheiro | 30 de Junho de 2026 A | 2.525 | 0 | 0 | $0 |
| Edward J Rapp | Conselheiro | 30 de Junho de 2026 A | 45.964 | 0 | 0 | $0 |
| Frederick H Waddell | Conselheiro | 8 de Maio de 2026 A | 30.076 | 0 | 0 | $0 |
| Thomas J Falk | Conselheiro | 8 de Maio de 2026 A | 2.321 | 0 | 0 | $0 |
| Roxanne S Austin | Conselheiro | 8 de Maio de 2026 A | 39.576 | 0 | 0 | $0 |
| Robert J Alpern | Conselheiro | 31 de Março de 2026 A | 35.646 | 0 | 0 | $0 |
| Jennifer L. Davis | Conselheiro | 9 de Maio de 2025 A | 2.525 | 0 | 0 | $0 |
| Melody B Meyer | Conselheiro | 9 de Maio de 2025 A | 16.498 | 0 | 0 | $0 |
| William H.L. Burnside | Conselheiro | 9 de Maio de 2025 A | 26.958 | 0 | 0 | $0 |
| Brett J Hart | Conselheiro | 9 de Maio de 2025 A | 19.472 | 0 | 0 | $0 |
| Glenn F Tilton | Conselheiro | 9 de Maio de 2025 A | 51.564 | 0 | 0 | $0 |
| Richard A Gonzalez | Conselheiro | 31 de Março de 2025 G | 386.479 | 0 | 0 | $0 |
| Edward M Liddy | Conselheiro | 31 de Março de 2022 A | 26.683 | 0 | 0 | $0 |
| Roy S Roberts | Conselheiro | 8 de Maio de 2015 A | 27.486 | 0 | 0 | $0 |
| AbbVie Inc. | Detentor de 10% | 28 de Março de 2017 S | 1.190.473 | 0 | 0 | $0 |
| ABBOTT LABORATORIES | Detentor de 10% | 12 de Dezembro de 2012 J | 0 | 0 | 0 | $0 |
| Rebecca B Roberts | — | 8 de Maio de 2026 A | 14.846 | 0 | 0 | $0 |
| Thomas C Freyman | — | 8 de Maio de 2026 A | 127.869 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 1 participação
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| AbbVie Inc. | 6 de Outubro de 2017 | — | Declaração inicial | M&A / venda | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 301 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 7,39% | 10.640 NS | 30 de Junho de 2026 | N-PORT |
| IYH · iShares Trust | 7,16% | 1.056.138 SH | 21 de Agosto de 2026 | Diário |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 6,58% | 3.464 NS | 30 de Abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 6,56% | 5.317.086 SH | 19 de Agosto de 2026 | Diário |
| HDV · iShares Trust | 6,21% | 3.641.083 SH | 21 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 6,03% | 814.750 NS | 30 de Abril de 2026 | N-PORT |
| RXL · ProShares Trust | 5,57% | 18.435 NS | 31 de Maio de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 5,39% | 35.243 NS | 30 de Abril de 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 5,39% | 108.712 SH | 21 de Agosto de 2026 | Diário |
| IXJ · iShares Trust | 4,97% | 825.161 SH | 21 de Agosto de 2026 | Diário |
| MEDI · Harbor ETF Trust | 4,78% | 6.235 NS | 30 de Abril de 2026 | N-PORT |
| LCOW · Pacer Funds Trust | 4,28% | 4.651 NS | 30 de Abril de 2026 | N-PORT |
| FLAG · Global X Funds | 4,27% | 333 NS | 30 de Abril de 2026 | N-PORT |
| PSIL · AdvisorShares Trust | 4,14% | 7.318 NS | 30 de Junho de 2026 | N-PORT |
| FDV · Federated Hermes ETF Trust | 3,86% | 136.965 NS | 30 de Abril de 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 3,73% | 264.051 SH | 21 de Agosto de 2026 | Diário |
| DIVL · Madison ETFs Trust | 3,68% | 8.786 NS | 30 de Junho de 2026 | N-PORT |
| USMC · Principal Exchange-Traded Funds | 3,39% | 470.441 NS | 30 de Junho de 2026 | N-PORT |
| AGNG · Global X Funds | 3,16% | 11.869 NS | 31 de Maio de 2026 | N-PORT |
| DGRO · iShares Trust | 3,04% | 5.059.458 SH | 21 de Agosto de 2026 | Diário |
| ABOT · Abacus FCF ETF Trust | 2,85% | 594 NS | 30 de Abril de 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,81% | 22.700 NS | 31 de Maio de 2026 | N-PORT |
| PAYR · Federated Hermes ETF Trust | 2,69% | 4.656 NS | 30 de Abril de 2026 | N-PORT |
| QDEF · FlexShares Trust | 2,66% | 66.732 NS | 30 de Abril de 2026 | N-PORT |
| QDF · FlexShares Trust | 2,63% | 264.330 NS | 30 de Abril de 2026 | N-PORT |
| SNPV · DBX ETF Trust | 2,62% | 27.726 NS | 29 de Maio de 2026 | N-PORT |
| BRIF · FIS Trust | 2,50% | 16.907 NS | 31 de Maio de 2026 | N-PORT |
| ABFL · Abacus FCF ETF Trust | 2,48% | 58.404 NS | 30 de Abril de 2026 | N-PORT |
| XT · iShares Trust | 2,47% | 372.278 SH | 21 de Agosto de 2026 | Diário |
| DIVY · Tidal Trust I | 2,42% | 3.163 NS | 31 de Maio de 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,40% | 5.714 NS | 31 de Maio de 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,35% | 498 NS | 30 de Abril de 2026 | N-PORT |
| FLCC · Federated Hermes ETF Trust | 2,20% | 12.240 NS | 31 de Maio de 2026 | N-PORT |
| VUSE · ETF Series Solutions | 2,15% | 67.918 NS | 31 de Maio de 2026 | N-PORT |
| QLV · FlexShares Trust | 2,13% | 17.108 NS | 30 de Abril de 2026 | N-PORT |
| CGCV · Capital Group Conservative Equity E… | 2,13% | 171.487 NS | 31 de Maio de 2026 | N-PORT |
| MGV · VANGUARD WORLD FUND | 2,10% | 1.110.490 SH | 19 de Agosto de 2026 | Diário |
| FDIV · EA Series Trust | 2,10% | 7.229 NS | 30 de Abril de 2026 | N-PORT |
| FLCG · Federated Hermes ETF Trust | 2,04% | 53.408 NS | 31 de Maio de 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 2,03% | 19.271 NS | 30 de Junho de 2026 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 1,99% | 69.180.000 | 21 de Agosto de 2026 | Diário |
| VIG · VANGUARD SPECIALIZED FUNDS | 1,94% | 9.981.469 SH | 19 de Agosto de 2026 | Diário |
| PJFV · PGIM ETF Trust | 1,90% | 7.518 NS | 29 de Maio de 2026 | N-PORT |
| SWP · Manager Directed Portfolios | 1,89% | 13.423 NS | 31 de Maio de 2026 | N-PORT |
| CDEI · Morgan Stanley ETF Trust | 1,88% | 1.357 NS | 30 de Junho de 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 1,87% | 4.006 NS | 30 de Abril de 2026 | N-PORT |
| SDOG · ALPS ETF Trust | 1,87% | 118.805 NS | 31 de Maio de 2026 | N-PORT |
| ANEW · ProShares Trust | 1,86% | 661 NS | 31 de Maio de 2026 | N-PORT |
| VYM · VANGUARD WHITEHALL FUNDS | 1,85% | 7.067.444 SH | 19 de Agosto de 2026 | Diário |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 1,82% | 54.664.000 | 21 de Agosto de 2026 | Diário |